Related Experiment Videos
History of parenteral nutrition in pediatrics with emphasis on amino acids
Insights
Total parenteral nutrition (TPN) is vital for newborns with GI issues but can cause hyperglycemia in premature infants. A revised TPN approach, focusing on energy expenditure, offers a safer alternative for these vulnerable infants.
Area of Science:
- Neonatal Medicine
- Pediatric Nutrition
- Biochemistry
Background:
- Central venous total parenteral nutrition (TPN) is a critical intervention for neonates with gastrointestinal anomalies or intractable diarrhea.
- Established TPN regimens pose significant hyperglycemia risks in low and very low birth weight infants.
Observation:
- Premature infants in a thermally neutral environment have energy expenditures typically not exceeding 50 kcal/kg.
- The evolution of parenteral amino acid solutions includes protein hydrolysates (first generation) and crystalline L-amino acids (second generation).
- Direct patient studies revealed limitations of second-generation solutions, necessitating specialized formulations.
Findings:
- A modified TPN approach, respecting the lower energy needs of premature infants, mitigates hyperglycemia risks.
- Third-generation amino acid solutions are specifically designed for metabolic conditions like renal failure, liver failure, trauma, and promoting anabolism.
- These specialized solutions represent a significant advancement in parenteral nutrition therapy.
Implications:
- This tailored TPN strategy enhances safety and efficacy for high-risk neonates.
- Future developments in parenteral nutrition will likely focus on precise solutions for specific metabolic disorders.
- Optimized amino acid formulations are crucial for improving outcomes in critically ill infants receiving TPN.
Abstract:
Central venous total parenteral nutrition (TPN) has proved to be a valuable and often life-saving measure in selected newborn infants with surgically repairable, major anomalies of the gastrointestinal tract and infants with chronic intractable diarrhea. However, in infants of low--and especially very low--birth weight, the TPN regimen that was so successful in older infants was frequently associated with severe risks of hyperglycemia. An alternative approach that has proved to be the most satisfactory relies on the fact that the energy expenditure of a premature infant, nursing in a thermally neutral environment, rarely exceeds 50 kcal/kg, a level that can be safely and effectively maintained. With respect to the development of parenteral amino acid solutions, three generations of such mixtures can now be identified. The first of these was represented by the protein hydrolysates. With the advent of technology for the production of pure L-amino acids, a second generation of crystalline mixtures was developed. Evaluation of these revealed that extrapolation from data on oral nutrition was often unsatisfactory for the adequate formulation of such mixtures. The direct study of the parenterally nourished patient led to the third generation of special purpose amino acid solutions such as those targeted for patients with renal failure, liver failure, or trauma or for the promotion of anabolism. It seems likely that development of other solutions will follow the trend of relying on accurate definition of a given metabolic disorder and the perfection of a specific solution to correct it.